Hologic, Inc. Hologic, Inc.

Hologic, Inc.

HOLX

Rang in Aktien #1327
Hologic, Inc. is a medical technology company focused on designing, producing,... Hologic, Inc. is a medical technology company focused on designing, producing, and marketing a diverse range of diagnostic tests, medical imaging systems, and surgical solutions. Its core mission is to enhance women's health through proactive detection and effective treatment, serving patients in the United States, across Europe, the Asia-Pacific region, and various other international markets. The company operates through four distinct business units: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Within its Diagnostics segment, Hologic provides Aptima molecular diagnostic assays for identifying infectious microorganisms, alongside Aptima viral load tests for conditions like HIV, Hepatitis C, and Hepatitis B. It also offers Aptima and Panther Fusion SARS-CoV-2 assays for detecting the virus, the ThinPrep System for cytology applications, and the Rapid Fetal Fibronectin Test to help clinicians assess the likelihood of premature birth. Furthermore, the company supplies various diagnostic tests for Group B Streptococcus. The Breast Health division delivers advanced imaging and analytical solutions, including 2D and 3D digital mammography systems with accompanying reading workstations. This segment also features minimally invasive breast biopsy guidance systems and devices, products for marking and localizing breast biopsy sites, specimen radiology tools, ultrasound solutions, connectivity options, and products supporting breast-conserving surgical procedures. For GYN Surgical needs, Hologic offers the NovaSure Endometrial Ablation System, designed to manage abnormal uterine bleeding, and the MyoSure Hysteroscopic Tissue Removal System for the excision of uterine fibroids, polyps, and other pathologies. Additionally, the Fluent Fluid Management System facilitates liquid distention during diagnostic and operative hysteroscopic interventions. The Skeletal Health segment includes the Horizon DXA, a dual-energy X-ray system, and the Fluoroscan Insight FD mini C-arm, which is utilized for minimally invasive orthopedic surgical procedures. Hologic distributes its comprehensive product portfolio through a combination of its dedicated direct sales and service teams, as well as via independent distributors and sales representatives. Established in 1985, Hologic, Inc. maintains its corporate headquarters in Marlborough, Massachusetts.
Aktienkurs
$76.01
Zuletzt synchronisiert: 2026-04-07
Marktkapitalisierung
$16.97B
Veränderung (1 Tag)
0.00%
Veränderung (1 Jahr)
5.76%
Land
US
Handel Hologic, Inc. (HOLX)

Kategorie

Healthcare
Gewinn für Hologic, Inc. (HOLX)
Gewinn im Dec 2025 TTM: $663.60M
Laut den aktuellen Finanzberichten von Hologic, Inc. betragen die aktuellen Gewinne des Unternehmens $663.60M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $865.10M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $676.10M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Hologic, Inc. von 2000 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
2026 (TTM) $663.60M -2.58%
2025 $681.20M -21.26%
2024 $865.10M 27.95%
2023 $676.10M -57.43%
2022 $1.59B -32.73%
2021 $2.36B 135.66%
2020 $1.00B -1,151.31%
2019 $-95.30M -77.23%
2018 $-418.60M -134.02%
2017 $1.23B 196.29%
2016 $415.30M 134.37%
2015 $177.20M 268.40%
2014 $48.10M -104.03%
2013 $-1.19B 1,834.71%
2012 $-61.66M -127.12%
2011 $227.39M -513.50%
2010 $-54.99M -97.37%
2009 $-2.09B 648.25%
2008 $-279.14M -287.99%
2007 $148.49M 178.99%
2006 $53.22M 53.40%
2005 $34.70M 168.39%
2004 $12.93M 295.93%
2003 $3.27M -1,406.00%
2002 $-250.00K -98.79%
2001 $-20.68M -28.73%
2000 $-29.02M 0.00%
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
$3.81B 473.51%
US
$4.11B 519.17%
FR
- -
JP
$1.59B 139.60%
US
- -
CH